metronidazole and Adnexitis studies

Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.
metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.

Adnexitis: Inflammation of the uterine appendages (ADNEXA UTERI) including infection of the FALLOPIAN TUBES (SALPINGITIS), the ovaries (OOPHORITIS), or the supporting ligaments (PARAMETRITIS).

Research Excerpts

Excerpt	Relevance	Reference
"A multicentre, randomised non-inferiority trial compared the efficacy and safety of 14 days of ofloxacin and metronidazole (standard-of-care (SoC)) versus a single dose of intramuscular ceftriaxone followed by 5 days of azithromycin and metronidazole (intervention arm (IA)) in women with mild-to-moderate pelvic inflammatory disease (PID)."	9.41	Treatment of mild-to-moderate pelvic inflammatory disease with a short-course azithromycin-based regimen versus ofloxacin plus metronidazole: results of a multicentre, randomised controlled trial. ( Dean, G; Pitt, R; Ross, J; Sabin, C; Soni, S; Whetham, J, 2021)
"To evaluate the efficacy and safety of moxifloxacin versus ofloxacin plus metronidazole in patients with uncomplicated pelvic inflammatory disease (uPID; defined as PID symptoms and signs, but no complications such as septicemia, perihepatitis, and tubo-ovarian abscess) in Turkey."	9.17	Single daily dose of moxifloxacin versus ofloxacin plus metronidazole as a new treatment approach to uncomplicated pelvic inflammatory disease: a multicentre prospective randomized trial. ( Ark, C; Aşicioğlu, O; Ertas, IE; Gungorduk, K; Ozdemir, A; Sanci, M; Yildirim, G, 2013)
"To evaluate the efficacy and safety of moxifloxacin versus levofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease (uPID) in Asia."	9.14	Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. ( Arvis, P; Hampel, B; Judlin, P; Liao, Q; Liu, Z; Reimnitz, P, 2010)
"This multicentre, double-blind study was undertaken to demonstrate non-inferiority of once-daily oral moxifloxacin compared with combination therapy in the management of acute, uncomplicated pelvic inflammatory disease (PID)."	9.14	A randomized double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease. ( Heystek, M; Ross, JD, 2009)
"This multinational, multicentre, prospective, randomised, double blind, parallel group, non-inferiority study compared the efficacy and safety of moxifloxacin monotherapy with ofloxacin plus metronidazole in women with uncomplicated pelvic inflammatory disease."	9.12	Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial. ( Alefelder, M; Arvis, P; Cronjé, HS; Kureishi, A; Paszkowski, T; Rakoczi, I; Reimnitz, P; Ross, JD; Vildaite, D, 2006)
"One hundred and sixty five women with diagnosis of pelvic inflammatory disease were randomized into three equal groups getting ciprofloxacin (500 mg) and tinidazole (600 mg) combination twice daily for 7 days (Group 1), a kit containing fluconazole (150 mg), azithromycin (1 gm) and secnidazole (2 mg) as one time dose (Group 2) and Doxycycline 100mg twice daily and metronidazole 200 mg thrice daily for seven days (Group 3)."	9.10	Ciprofloxacin-tinidazole combination, fluconazole- azithromicin-secnidazole-kit and doxycycline- metronidazole combination therapy in syndromic management of pelvic inflammatory disease: a prospective randomized controlled trial. ( Arora, R; Batra, S; Malhotra, M; Sharma, JB; Sharma, S, 2003)
"The purpose of this study was to evaluate the effect of metronidazole treatment on the incidence of postoperative pelvic inflammatory disease after first-trimester abortion in women with bacterial vaginosis."	9.07	Incidence of pelvic inflammatory disease after first-trimester legal abortion in women with bacterial vaginosis after treatment with metronidazole: a double-blind, randomized study. ( Forsum, U; Larsson, PG; Påhlson, C; Platz-Christensen, JJ; Thejls, H, 1992)
"110 patients suffering from laparoscopical verified salpingitis and desire for a baby, were treated with tetracycline (oxytetracycline or doxycycline; TC)/metronidazole (n = 67), augmentan (n = 22) or cipropfloxacin/metronidazole (n = 21)."	9.07	[Treatment of acute salpingitis with tetracycline/metronidazole with or without additional balneotherapy, Augmentin or ciprofloxacin/metronidazole: a second-look laparoscopy study]. ( Barten, G; Gerber, B; Splitt, G; Wilken, H; Zacharias, K, 1992)
"A double-blind, randomised study was conducted to compare the efficacy and safety of a combination of pefloxacin and metronidazole versus doxycycline and metronidazole in patients with pelvic inflammatory disease (PID)."	9.07	A comparison of pefloxacin/metronidazole and doxycycline/metronidazole in the treatment of laparoscopically confirmed acute pelvic inflammatory disease. ( Mouton, RP; Peters, AA; Smit, IB; van der Linden, MC; van der Meer, JW; van Erp, EJ; Witte, EH, 1993)
"A randomized, multi-centre trial was carried out in 152 hospitalized women with pelvic inflammatory disease to evaluate the efficacy and tolerability of amoxycillin/clavulanic acid compared with that of a standard regimen using three antimicrobial agents (aminopenicillin, an aminoglycoside and metronidazole)."	9.06	Amoxycillin/clavulanic acid ('Augmentin') compared with a combination of aminopenicillin, aminoglycoside and metronidazole in the treatment of pelvic inflammatory disease. ( Barrier, J; Becue, J; Chartier, M; Cirau-Vigneron, N; Giraud, JR; Landes, P; Leng, J; Raudrant, D; Reme, JM, 1989)
"In a double-blind controlled trial the efficacy of prophylactic metronidazole and pivampicillin to women with a history of pelvic inflammatory disease (PID) undergoing first-trimester abortion was assessed."	9.06	Comparison of preventive use of metronidazole and ampicillin in women with a history of pelvic inflammatory disease undergoing first-trimester abortion. ( Heisterberg, L; Nielsen, D; Petersen, K; Sørensen, SS, 1986)
"Large randomized controlled trials support the efficacy of moxifloxacin for the treatment of uncomplicated pelvic inflammatory disease (PID)."	7.76	A comparison of treatment outcomes for moxifloxacin versus ofloxacin/metronidazole for first-line treatment of uncomplicated non-gonococcal pelvic inflammatory disease. ( Boothby, M; Page, J; Pryor, R; Ross, JD, 2010)
" The most common treatment-related adverse event was diarrhea (23."	6.80	Efficacy and safety of metronidazole injection for the treatment of infectious peritonitis, abdominal abscess and pelvic inflammatory diseases in Japan. ( Matsumizu, M; Mikamo, H; Nagashima, M; Nakazuru, Y, 2015)
"Uncomplicated pelvic inflammatory disease (PID) is a common disease caused by numerous pathogens: sexually transmitted infections (such as Chlamydia trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium), anaerobes, and other organisms from the vaginal flora."	6.74	Levofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: a preliminary study. ( Judlin, P; Thiebaugeorges, O, 2009)
"Ciprofloxacin treatment was successful in all nine patients with chlamydial or gonococcal PID and in six of seven with nonchlamydial nongonococcal PID."	6.66	A comparison of ciprofloxacin with doxycycline plus metronidazole in the treatment of acute pelvic inflammatory disease. ( Aine, R; Grönroos, P; Heinonen, PK; Miettinen, A; Punnonen, R; Teisala, K, 1989)
"59 patients with acute pelvic inflammatory diseases proved and classified by laparoscopy were treated by two kinds of therapies in alternating order."	6.66	[Adjuvant prednisolone therapy for the prevention of adhesions after acute adnexitis]. ( Akkermann, N; Kolmorgen, K, 1988)
"A multicentre, randomised non-inferiority trial compared the efficacy and safety of 14 days of ofloxacin and metronidazole (standard-of-care (SoC)) versus a single dose of intramuscular ceftriaxone followed by 5 days of azithromycin and metronidazole (intervention arm (IA)) in women with mild-to-moderate pelvic inflammatory disease (PID)."	5.41	Treatment of mild-to-moderate pelvic inflammatory disease with a short-course azithromycin-based regimen versus ofloxacin plus metronidazole: results of a multicentre, randomised controlled trial. ( Dean, G; Pitt, R; Ross, J; Sabin, C; Soni, S; Whetham, J, 2021)
"Acute pelvic inflammatory disease is associated with significant adverse reproductive sequelae."	5.28	Sulbactam/ampicillin in the treatment of acute pelvic inflammatory disease. ( Crombleholme, WR; Landers, DV; Schachter, J; Sweet, RL, 1989)
"Ciprofloxacin was less effective than combination treatment against Gardnerella vaginalis."	5.28	The effect of ciprofloxacin and doxycycline plus metronidazole on lower genital tract flora in patients with proven pelvic inflammatory disease. ( Heinonen, PK; Laine, S; Miettinen, A; Teisala, K, 1991)
"The best way of treating pelvic inflammatory disease (PID) is not known."	5.27	Treating pelvic inflammatory disease with doxycycline and metronidazole or penicillin and metronidazole. ( Aine, R; Heinonen, PK; Lehtinen, M; Miettinen, A; Paavonen, J; Punnonen, R; Teisala, K, 1986)
"To evaluate the efficacy and safety of moxifloxacin versus ofloxacin plus metronidazole in patients with uncomplicated pelvic inflammatory disease (uPID; defined as PID symptoms and signs, but no complications such as septicemia, perihepatitis, and tubo-ovarian abscess) in Turkey."	5.17	Single daily dose of moxifloxacin versus ofloxacin plus metronidazole as a new treatment approach to uncomplicated pelvic inflammatory disease: a multicentre prospective randomized trial. ( Ark, C; Aşicioğlu, O; Ertas, IE; Gungorduk, K; Ozdemir, A; Sanci, M; Yildirim, G, 2013)
"This multicentre, double-blind study was undertaken to demonstrate non-inferiority of once-daily oral moxifloxacin compared with combination therapy in the management of acute, uncomplicated pelvic inflammatory disease (PID)."	5.14	A randomized double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease. ( Heystek, M; Ross, JD, 2009)
"To evaluate the efficacy and safety of moxifloxacin versus levofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease (uPID) in Asia."	5.14	Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. ( Arvis, P; Hampel, B; Judlin, P; Liao, Q; Liu, Z; Reimnitz, P, 2010)
"This multinational, multicentre, prospective, randomised, double blind, parallel group, non-inferiority study compared the efficacy and safety of moxifloxacin monotherapy with ofloxacin plus metronidazole in women with uncomplicated pelvic inflammatory disease."	5.12	Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial. ( Alefelder, M; Arvis, P; Cronjé, HS; Kureishi, A; Paszkowski, T; Rakoczi, I; Reimnitz, P; Ross, JD; Vildaite, D, 2006)
"One hundred and sixty five women with diagnosis of pelvic inflammatory disease were randomized into three equal groups getting ciprofloxacin (500 mg) and tinidazole (600 mg) combination twice daily for 7 days (Group 1), a kit containing fluconazole (150 mg), azithromycin (1 gm) and secnidazole (2 mg) as one time dose (Group 2) and Doxycycline 100mg twice daily and metronidazole 200 mg thrice daily for seven days (Group 3)."	5.10	Ciprofloxacin-tinidazole combination, fluconazole- azithromicin-secnidazole-kit and doxycycline- metronidazole combination therapy in syndromic management of pelvic inflammatory disease: a prospective randomized controlled trial. ( Arora, R; Batra, S; Malhotra, M; Sharma, JB; Sharma, S, 2003)
"To determine the prevalence of bacterial vaginosis in women undergoing first trimester suction termination of pregnancy and to evaluate the efficacy of metronidazole in reducing the risk of post abortal pelvic infection in women with bacterial vaginosis."	5.09	Antibiotic prophylaxis to prevent post-abortal upper genital tract infection in women with bacterial vaginosis: randomised controlled trial. ( Bidgood, K; Crowley, T; Harvey, I; Horner, P; Low, N; Turner, A, 2001)
"The purpose of this study was to evaluate the effect of metronidazole treatment on the incidence of postoperative pelvic inflammatory disease after first-trimester abortion in women with bacterial vaginosis."	5.07	Incidence of pelvic inflammatory disease after first-trimester legal abortion in women with bacterial vaginosis after treatment with metronidazole: a double-blind, randomized study. ( Forsum, U; Larsson, PG; Påhlson, C; Platz-Christensen, JJ; Thejls, H, 1992)
"110 patients suffering from laparoscopical verified salpingitis and desire for a baby, were treated with tetracycline (oxytetracycline or doxycycline; TC)/metronidazole (n = 67), augmentan (n = 22) or cipropfloxacin/metronidazole (n = 21)."	5.07	[Treatment of acute salpingitis with tetracycline/metronidazole with or without additional balneotherapy, Augmentin or ciprofloxacin/metronidazole: a second-look laparoscopy study]. ( Barten, G; Gerber, B; Splitt, G; Wilken, H; Zacharias, K, 1992)
"A double-blind, randomised study was conducted to compare the efficacy and safety of a combination of pefloxacin and metronidazole versus doxycycline and metronidazole in patients with pelvic inflammatory disease (PID)."	5.07	A comparison of pefloxacin/metronidazole and doxycycline/metronidazole in the treatment of laparoscopically confirmed acute pelvic inflammatory disease. ( Mouton, RP; Peters, AA; Smit, IB; van der Linden, MC; van der Meer, JW; van Erp, EJ; Witte, EH, 1993)
"A randomized, multi-centre trial was carried out in 152 hospitalized women with pelvic inflammatory disease to evaluate the efficacy and tolerability of amoxycillin/clavulanic acid compared with that of a standard regimen using three antimicrobial agents (aminopenicillin, an aminoglycoside and metronidazole)."	5.06	Amoxycillin/clavulanic acid ('Augmentin') compared with a combination of aminopenicillin, aminoglycoside and metronidazole in the treatment of pelvic inflammatory disease. ( Barrier, J; Becue, J; Chartier, M; Cirau-Vigneron, N; Giraud, JR; Landes, P; Leng, J; Raudrant, D; Reme, JM, 1989)
"In a double-blind controlled trial the efficacy of prophylactic metronidazole and pivampicillin to women with a history of pelvic inflammatory disease (PID) undergoing first-trimester abortion was assessed."	5.06	Comparison of preventive use of metronidazole and ampicillin in women with a history of pelvic inflammatory disease undergoing first-trimester abortion. ( Heisterberg, L; Nielsen, D; Petersen, K; Sørensen, SS, 1986)
"In a double-blind controlled trial the effect of prophylactic metronidazole on postabortal infection in women with a history of pelvic inflammatory disease (PID) was assessed."	5.06	Prophylactic antibiotics in women with a history of pelvic inflammatory disease undergoing first-trimester abortion. ( Heisterberg, L, 1987)
"The efficacy and safety of two antibiotic combination (clindamycin + gentamycin [C + G] versus metronidazole + gentamycin [M + G]) have been compared in 45 in-patients suffering from pelvic inflammatory disease in a clinical prospective randomized trial."	5.06	[Prospective randomized study comparing the efficacy and tolerance of clindamycin-gentamycin versus metronidazole-gentamycin in acute utero-adnexal infections in hospitalized patients]. ( Cacault, JA; Engelman, P; Lebceuf, D; Rousset, D, 1987)
"One hundred forty-six consecutive inpatients with acute pelvic inflammatory disease (PID) were randomly treated either with the combination of doxycycline and metronidazole or with the combination of penicillin G/amoxicillin and metronidazole."	5.05	Factors predicting abnormal hysterosalpingographic findings in patients treated for acute pelvic inflammatory disease. ( Aantaa, K; Paavonen, J; Räsänen, J; Vesterinen, E, 1985)
"Large randomized controlled trials support the efficacy of moxifloxacin for the treatment of uncomplicated pelvic inflammatory disease (PID)."	3.76	A comparison of treatment outcomes for moxifloxacin versus ofloxacin/metronidazole for first-line treatment of uncomplicated non-gonococcal pelvic inflammatory disease. ( Boothby, M; Page, J; Pryor, R; Ross, JD, 2010)
"In the United Kingdom many genitourinary medicine clinics use oral doxycycline and metronidazole to treat pelvic inflammatory disease (PID)."	3.73	Improvement in the clinical cure rate of outpatient management of pelvic inflammatory disease following a change in therapy. ( Piyadigamage, A; Wilson, J, 2005)
" A total of 83 patients with PID were randomly divided into two groups: Western medicine group (control group, n=41) received oral antibiotics (azithromycin + metronidazole) alone and the traditional Chinese medicine combined with Western medicine group (experimental group, n=42) received Kangfuyan capsule based on Western medicine therapy."	3.01	Curative effect of kangfuyan capsule combined with antibiotic treatment on pelvic inflammatory disease. ( Chen, X; Chen, Y; Ouyang, YL; Wang, FW; Wang, L; Zhang, RJ, 2021)
"To investigate the effect of Fuyanshu Capsules combined with Western medicine antibiotics on symptoms and inflammatory factors IL-10 and IL-1β in patients with pelvic inflammatory disease and its possible mechanism."	2.90	[Effect of Fuyanshu Capsules combined with antibiotics on inflammatory factors in patients with pelvic inflammatory disease]. ( Chen, J; Chen, L; Feng, XL; Jiang, S; Liu, X; Zhang, Y, 2019)
" The most common treatment-related adverse event was diarrhea (23."	2.80	Efficacy and safety of metronidazole injection for the treatment of infectious peritonitis, abdominal abscess and pelvic inflammatory diseases in Japan. ( Matsumizu, M; Mikamo, H; Nagashima, M; Nakazuru, Y, 2015)
"Uncomplicated pelvic inflammatory disease (PID) is a common disease caused by numerous pathogens: sexually transmitted infections (such as Chlamydia trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium), anaerobes, and other organisms from the vaginal flora."	2.74	Levofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: a preliminary study. ( Judlin, P; Thiebaugeorges, O, 2009)
"Ciprofloxacin treatment was successful in all nine patients with chlamydial or gonococcal PID and in six of seven with nonchlamydial nongonococcal PID."	2.66	A comparison of ciprofloxacin with doxycycline plus metronidazole in the treatment of acute pelvic inflammatory disease. ( Aine, R; Grönroos, P; Heinonen, PK; Miettinen, A; Punnonen, R; Teisala, K, 1989)
"Follow-up is required in women with sexually transmitted infections (STIs) (grade C)."	2.66	Pelvic inflammatory diseases: Updated French guidelines. ( Brun, JL; Castan, B; Cazanave, C; Charvériat, A; de Barbeyrac, B; Faure, K; Fritel, X; Graesslin, O; Mignot, S; Verdon, R, 2020)
"30 patients had severe acute pelvic inflammatory disease with peritonitis, 3 tubo-ovarian abscesses, 4 endomyometritis, and 2 posthysterectomy pelvic cellulitis."	2.66	Sulbactam/ampicillin versus metronidazole/gentamicin in the treatment of severe pelvic infections. ( Crombleholme, W; Dahrouge, D; DeKay, V; Hadley, WK; Landers, D; Ohm-Smith, M; Robbie, MO; Sweet, RL, 1986)
"59 patients with acute pelvic inflammatory diseases proved and classified by laparoscopy were treated by two kinds of therapies in alternating order."	2.66	[Adjuvant prednisolone therapy for the prevention of adhesions after acute adnexitis]. ( Akkermann, N; Kolmorgen, K, 1988)
"Forty-four patients with severe pelvic inflammatory disease were randomly divided into two groups."	2.66	[The drug combination amoxicillin-clavulanic acid compared to the triple combination ampicillin-gentamicin-metronidazole in the treatment of severe adnexal infections]. ( Barrier, J; Bercau, G; Ciraru-Vigneron, N; Felten, A; Leaute, JB; Nguyen Tan Lung, R; Sauvanet, E; Zylbertrest, T, 1986)
"Of 25 women with a positive history of pelvic inflammatory disease, six contracted postabortal infection, which was a significantly increased frequency compared with women without previous episodes of pelvic inflammatory disease (P less than ."	2.66	Metronidazole prophylaxis in elective first trimester abortion. ( Heisterberg, L; Petersen, K, 1985)
"Whether bacterial vaginosis (BV) is acquired from an endogenous or an exogenous source is subject to controversy."	2.43	Bacterial vaginosis. Transmission, role in genital tract infection and pregnancy outcome: an enigma. ( Bergström, M; Forsum, U; Jacobsson, B; Larsson, PG; Strand, A; Wölner-Hanssen, P, 2005)
"The latter category includes pelvic inflammatory disease, pelvic thrombophlebitis, septic abortion, and premature rupture of the membranes."	2.36	Infections in the female genital tract. ( Gall, SA, 1983)
"Most patients (81%) with pelvic inflammatory disease were diagnosed as having chlamydia alone."	1.48	Gonococcal and Chlamydial Cases of Pelvic Inflammatory Disease at 2 Canadian Sexually Transmitted Infection Clinics, 2004 to 2014: A Retrospective Cross-sectional Review. ( Chen, JZ; Gratrix, J; Parker, P; Read, R; Singh, AE; Smyczek, P, 2018)
"Prompt and effective treatment of pelvic inflammatory disease (PID) may help prevent long-term complications."	1.36	Management of first-episode pelvic inflammatory disease in primary care: results from a large UK primary care database. ( Cassell, J; Hughes, G; Mercer, CH; Murray-Thomas, T; Nicholson, A; Rait, G, 2010)
"Acute pelvic inflammatory disease is associated with significant adverse reproductive sequelae."	1.28	Sulbactam/ampicillin in the treatment of acute pelvic inflammatory disease. ( Crombleholme, WR; Landers, DV; Schachter, J; Sweet, RL, 1989)
"Sixty Jordanian women with pelvic inflammatory disease (PID) were studied."	1.28	Amoxycillin/clavulanic acid (augmentin) compared with triple drug therapy for pelvic inflammatory disease. ( Barakat, HF; Dajani, YF; Masoud, AA; Sartawi, SA; Uri, FI, 1992)
"Ciprofloxacin was less effective than combination treatment against Gardnerella vaginalis."	1.28	The effect of ciprofloxacin and doxycycline plus metronidazole on lower genital tract flora in patients with proven pelvic inflammatory disease. ( Heinonen, PK; Laine, S; Miettinen, A; Teisala, K, 1991)
"The best way of treating pelvic inflammatory disease (PID) is not known."	1.27	Treating pelvic inflammatory disease with doxycycline and metronidazole or penicillin and metronidazole. ( Aine, R; Heinonen, PK; Lehtinen, M; Miettinen, A; Paavonen, J; Punnonen, R; Teisala, K, 1986)
"After laparoscopic confirmation of adnexitis, a bacteriological examination was made of specimens taken from the small pelvis of 63 patients, with an average age of 26."	1.27	[Bacteriologic findings and therapeutic consequences in adnexitis]. ( Krasemann, C; Mendling, W, 1986)
"A total of 40 patients with acute pelvic inflammatory disease (APID) were studied over a period of 7 months; one aim was to evaluate the use of different antibiotics in treatment."	1.27	Efficacy of different antibiotics in the treatment of pelvic inflammatory disease. ( Burchell, HJ; Cronjé, HS; de Wet, JI, 1987)

Research

Studies (79)

Authors

Clinical Trials (7)

Trial Overview

Trial Outcomes

Clearance of Anaerobic Organisms From the Endometrium

Timeframe	Studies, this research(%)	All Research%
pre-1990	24 (30.38)	18.7374
1990's	16 (20.25)	18.2507
2000's	15 (18.99)	29.6817
2010's	18 (22.78)	24.3611
2020's	6 (7.59)	2.80

Authors	Studies
Wang, L	1
Chen, Y	1
Ouyang, YL	1
Wang, FW	1
Zhang, RJ	1
Chen, X	1
Mitchell, C	1
Wiesenfeld, HC	2
Meyn, LA	1
Darville, T	1
Macio, IS	1
Hillier, SL	1
Brun, JL	3
Castan, B	1
de Barbeyrac, B	1
Cazanave, C	1
Charvériat, A	1
Faure, K	1
Mignot, S	1
Verdon, R	2
Fritel, X	1
Graesslin, O	2
Lam, R	1
Jamidar, PA	1
Aslanian, HR	1
Muniraj, T	1
Dean, G	1
Soni, S	1
Pitt, R	1
Ross, J	1
Sabin, C	1
Whetham, J	1
Pathak, M	1
Coombes, AGA	1
Ryu, B	1
Cabot, PJ	1
Turner, MS	1
Palmer, C	1
Wang, D	1
Steadman, KJ	1
Chen, JZ	1
Gratrix, J	1
Smyczek, P	1
Parker, P	1
Read, R	1
Singh, AE	1
Haumann, A	1
Ongaro, S	1
Detry, O	1
Meunier, P	1
Meurisse, M	1
Savaris, RF	1
Fuhrich, DG	1
Duarte, RV	1
Franik, S	1
Ross, JDC	1
Feng, XL	1
Jiang, S	1
Chen, J	1
Liu, X	1
Zhang, Y	1
Chen, L	1
Ugianskiene, A	1
Woods, JL	1
Scurlock, AM	1
Hensel, DJ	1
Aşicioğlu, O	1
Gungorduk, K	1
Ozdemir, A	1
Ertas, IE	1
Yildirim, G	1
Sanci, M	1
Ark, C	1
Mikamo, H	1
Matsumizu, M	1
Nakazuru, Y	1
Nagashima, M	1
Llata, E	1
Bernstein, KT	1
Kerani, RP	1
Pathela, P	1
Schwebke, JR	2
Schumacher, C	1
Stenger, M	1
Weinstock, HS	1
Fauconnier, A	2
Agostini, A	1
Bourret, A	2
Derniaux, E	1
Garbin, O	1
Huchon, C	1
Lamy, C	1
Quentin, R	1
Judlin, P	3
Garg, R	1
Zahra, F	1
Chandra, JA	1
Vatsal, P	1
Thiebaugeorges, O	1
Gensheimer, WG	1
Reddy, SY	1
Mulconry, M	1
Greves, C	1
Heystek, M	1
Ross, JD	4
Boothby, M	1
Page, J	1
Pryor, R	1
Mary, N	1
Mahmood, TA	1
Liao, Q	1
Liu, Z	1
Reimnitz, P	2
Hampel, B	1
Arvis, P	2
Nicholson, A	1
Rait, G	1
Murray-Thomas, T	1
Hughes, G	1
Mercer, CH	1
Cassell, J	1
Coleman, JS	1
Gaydos, CA	1
Witter, F	1
Ressel, GW	1
Altunyurt, S	1
Demir, N	1
Posaci, C	1
MIRSALIM, M	1
Heinonen, PK	6
Leinonen, M	1
Malhotra, M	1
Sharma, JB	1
Batra, S	1
Arora, R	1
Sharma, S	1
Das, S	1
Kirwan, J	1
Drakeley, AJ	1
Kingsland, CR	1
Larsson, PG	2
Bergström, M	1
Forsum, U	2
Jacobsson, B	1
Strand, A	1
Wölner-Hanssen, P	1
Piyadigamage, A	1
Wilson, J	1
Cronjé, HS	2
Paszkowski, T	1
Rakoczi, I	1
Vildaite, D	1
Kureishi, A	1
Alefelder, M	1
Desmond, R	1
Smith, KJ	1
Ness, RB	1
Roberts, MS	1
Gall, SA	1
Mitchell, RG	1
Crow, MR	1
Ogunbanjo, BO	1
Osoba, AO	1
Fischbach, F	1
Deckardt, R	1
Graeff, H	1
Witte, EH	1
Peters, AA	1
Smit, IB	1
van der Linden, MC	1
Mouton, RP	1
van der Meer, JW	1
van Erp, EJ	1
Schreiber, W	1
Spernal, J	1
Tepper, R	1
Aviram, R	1
Cohen, N	1
Cohen, I	1
Holtzinger, M	1
Beyth, Y	1
Gardó, S	1
Antonelli, D	1
Kustrup, JF	1
Crowley, T	1
Low, N	1
Turner, A	1
Harvey, I	1
Bidgood, K	1
Horner, P	1
Uri, FI	1
Sartawi, SA	1
Dajani, YF	1
Masoud, AA	1
Barakat, HF	1
Gerber, B	1
Wilken, H	1
Zacharias, K	1
Barten, G	1
Splitt, G	1
Platz-Christensen, JJ	1
Thejls, H	1
Påhlson, C	1
Rousseau, S	1
Morisset, ME	1
Knoefel, F	1
Gattereau, D	1
Morisset, R	1
McGregor, JA	1
Christensen, FB	1
French, JI	1
Varga, A	1
Lovas, J	1
Miettinen, A	4
Laine, S	1
Teisala, K	5
Hammond, TL	1
Hankins, GD	1
Snyder, RR	1
van Iddekinge, B	1
Davey, MR	1
Aine, R	4
Cirau-Vigneron, N	1
Barrier, J	2
Becue, J	1
Chartier, M	1
Giraud, JR	1
Landes, P	1
Leng, J	1
Raudrant, D	1
Reme, JM	1
Mola, G	1
Punnonen, R	3
Grönroos, P	1
Sweet, RL	2
Landers, DV	1
Schachter, J	1
Crombleholme, WR	1
Paavonen, J	3
Vesterinen, E	1
Aantaa, K	1
Räsänen, J	1
Heisterberg, L	3
Petersen, K	2
Sørensen, SS	1
Nielsen, D	1
Crombleholme, W	1
Landers, D	1
Ohm-Smith, M	1
Robbie, MO	1
Hadley, WK	1
DeKay, V	1
Dahrouge, D	1
Lehtinen, M	1
Kolmorgen, K	1
Akkermann, N	1
Koinzer, G	1
Walter, S	1
Peschke, KH	1
Wecke, WD	1
Mendling, W	1
Krasemann, C	1
Ciraru-Vigneron, N	1
Bercau, G	1
Sauvanet, E	1
Nguyen Tan Lung, R	1
Felten, A	1
Leaute, JB	1
Zylbertrest, T	1
Lebceuf, D	1
Rousset, D	1
Cacault, JA	1
Engelman, P	1
Burchell, HJ	1
de Wet, JI	1
Larsen, B	1
Wilson, AH	1
Glover, DD	1
Charles, D	1
Pejtsik, B	1
Tóth, E	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
The Importance of Anti-anaerobic Therapy for Acute PID[NCT01160640]	Phase 2	233 participants (Actual)	Interventional	2010-11-30	Completed
A Phase 3, Multicenter, Unblind, Non-Comparative Study To Confirm Efficacy And Safety Of Intravenous Metronidazole In Patients With Intrabdominal Infection In Combination With Intravenous Ceftriaxone[NCT01473836]	Phase 3	38 participants (Actual)	Interventional	2011-11-30	Completed
[NCT01799356]	Phase 4	1,303 participants (Actual)	Interventional	2010-06-30	Completed
A Prospective, Randomized, Double Dummy, Double Blind, Multi-center Multinational Trial Comparing the Efficacy and Safety of Moxifloxacin 400 mg PO QD 24 Hours for 14 Days to That of Levofloxacin 500 mg PO QD 24 Hours Plus Metronidazole 500 mg BID for 14 [NCT00453349]	Phase 3	460 participants (Actual)	Interventional	2007-01-31	Completed
Comparative Effectiveness Clinical Early of Transvaginal and Laparoscopic Approaches for Drainage of Tubo -Ovarian Abscess. Randomized Noninferiority[NCT03166982]		80 participants (Anticipated)	Interventional	2016-10-26	Recruiting
A Phase IIa Study of the Colonization Efficiency, Safety and Acceptability of LACTIN-V Administered Vaginally to Women With Bacterial Vaginosis[NCT00635622]	Phase 2	40 participants (Anticipated)	Interventional	2008-04-30	Completed
A Phase I Study of the Safety of LACTIN-V Administered Vaginally to Healthy Women[NCT00537576]	Phase 1	12 participants (Actual)	Interventional	2007-11-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Clearance of anaerobic microorganisms from the endometrium at the 30 day follow-up visit among women who had anaerobic microorganisms detected in their endometrial tissue sample at enrollment. Clearance is defined as no anaerobic microorganisms detected in the endometrial tissue biopsy sample collected at the 30-day visit. (NCT01160640)
Timeframe: Enrollment to 30 days

Identification of Endometrial Microorganisms Present Obtained From Women With or Without Evidence of Endometritis.

Intervention	participants (Number)
	Clearance of anaerobes	Anaerobes detected
Ceftriaxone, Doxycycline, Metronidazole	18	1
Ceftriaxone, Doxycycline, Placebo	14	7

Identification of endometrial microorganisms present obtained from women with or without evidence of endometritis using a combination of culture methods, rRna sequencing and whole genomic sequencing. The aim is to identify the etiology of endometritis. (NCT01160640)
Timeframe: enrollment

Resolution of Clinical Signs and Symptoms of Acute PID - Intention to Treat Analysis

Intervention	participants (Number)
	Chlamydia trachomatis	Neisseria gonorrhoeae	Mycoplasma genitalium	Haemophilus influenzae	Gardnerella vaginalis	Atopobium vaginae	Anaerobic gram negative rods	Anaerobic gram positive cocci	Anaerobic gram positive rods
Histological Endometritis Absent	5	2	5	1	25	13	8	11	11
Histological Endometritis Present	17	8	12	5	22	7	8	10	4

Clinical response to treatment is improvement (reduction) of the McCormack Scale total score from baseline to day 3 follow-up visit. Participants without a 3-day measure were considered treatment failures. (NCT01160640)
Timeframe: Enrollment to 3 day follow up visit

The Eradication of M. Genitalium From the Lower and Upper Genital Tract Following Antibiotic Therapy for Acute PID.

Intervention	participants (Number)
	Clinical response	No response
Ceftriaxone, Doxycycline, Metronidazole	96	20
Ceftriaxone, Doxycycline, Placebo	94	23

M. genitalium not detected in the cervical and endometrial cultures by nucleic acid amplification testing at the 30 day visit among women who had M. genitalium detected at either anatomical site at the enrollment visit. (NCT01160640)
Timeframe: Enrollment to 30 days

The Prevalence of M. Genitalium in the Cervix and Endometrium From Women With Acute PID.

Intervention	participants (Number)
	Not detected in cervix & endometrium	Detected in cervix or endometrium
Ceftriaxone, Doxycycline, Metronidazole	9	4
Ceftriaxone, Doxycycline, Placebo	8	13

The number of women who had M. genitalium detected in cervical and endometrial biopsy cultures by nucleic acid amplification tests at enrollment. (NCT01160640)
Timeframe: enrollment

Percentage of Participants Who Was Assessed as Appropriate to Continue Treatment (Investigator Assessment)

Intervention	participants (Number)
	Detected in cervix only	Detected in cervix and endometrium	Detected in endometrium only	Not detected in cervix and endometrium
Ceftriaxone, Doxycycline, Metronidazole	12	5	2	97
Ceftriaxone, Doxycycline, Placebo	16	8	3	90

"The appropriateness of treatment continuation was evaluated on Day 4 by the investigator as continuation, discontinuation or indeterminate based on the clinical response. The percentage of participants was calculated from the following formula; number of participants assessed as continuation over total number of participants that excluding ones assessed as indeterminate multiplied by 100." (NCT01473836)
Timeframe: Baseline to Day 4

Bacteriological Response: Eradication Rate (Data Review Committee Assessment)

Intervention	percentage of participants (Number)
Metronidazole/Ceftriaxone	100.0

"Bacteriological response was evaluated as eradication (eradication, presumed eradication or colonization), persistence, or indeterminate by the data review committee, at Day 4, at the end of treatment (EOT), and the test of cure (TOC: 7 days after EOT). Eradication Rate was calculated from the following formula, number of participants with bacteria eradication, presumed eradication or colonization over total number of participants that excluding ones evaluated as indeterminate multiplied by 100." (NCT01473836)
Timeframe: Baseline to Day 4, EOT (up to 14 days), TOC

Bacteriological Response: Eradication Rate (Investigator Assessment)

Intervention	percentage of participants (Number)
	Day 4	End of Treatment	Test of Cure
Metronidazole/Ceftriaxone	100.0	100.0	100.0

"Bacteriological response was evaluated as eradication (eradication, presumed eradication or colonization), persistence, or indeterminate by the investigator at the end of treatment (EOT), and the test of cure (TOC: 7 days after EOT). Eradication Rate was calculated from the following formula, number of participants with bacteria eradication, presumed eradication or colonization over total number of participants that excluding ones evaluated as indeterminate multiplied by 100." (NCT01473836)
Timeframe: Baseline to Day 4, EOT (up to 14 days), TOC

Clinical Response: Response Rate (Data Review Committee Assessment)

Intervention	percentage of participants (Number)
	Day 4	EOT	TOC
Metronidazole/Ceftriaxone	100.0	100.0	100.0

"Clinical response was evaluated by the data review committee as effective (cured or improved), ineffective (not meeting effective criteria), or indeterminate at the end of treatment (EOT) and the test of cure (TOC: 7 days after EOT) based on clinical symptoms, ultrasound images and necessity of other treatment. TOC was the primary analysis of this outcome measure. Cured = clinical symptoms and abnormal findings at the start of the study were disappeared and considered other antibiotics were not required during the study and after the assessment time point. Improved = clinical symptoms and abnormal findings at the start of the study were improved and considered other antibiotics were not required during the study and after the assessment time point. Response rate was calculated from the following formula; number of participants evaluated as effective over total number of participants that excluding ones evaluated as indeterminate multiplied by 100." (NCT01473836)
Timeframe: Baseline to EOT (up to 14 days), TOC

Clinical Response: Response Rate (Investigator Assessment)

Intervention	percentage of participants (Number)
	End of Treatment (n=30)	Test of Cure (n=30)
Metronidazole/Ceftriaxone	96.6	96.7

"Clinical response was evaluated by the investigator as effective (cured or improved), ineffective (not meeting effective criteria), or indeterminate at the end of treatment (EOT) and the test of cure (TOC: 7 days after EOT) based on clinical symptoms, ultrasound images and necessity of other treatment. TOC was the primary analysis of this outcome measure. Cured = clinical symptoms and abnormal findings at the start of the study were disappeared and considered other antibiotics were not required during the study and after the assessment time point. Improved = clinical symptoms and abnormal findings at the start of the study were improved and considered other antibiotics were not required during the study and after the assessment time point. Response rate was calculated from the following formula; number of participants evaluated as effective over total number of participants that excluding ones evaluated as indeterminate multiplied by 100." (NCT01473836)
Timeframe: Baseline to EOT (up to 14 days), TOC

Bacteriological Response at Follow-up Visit in Intent To Treat Population With Causative Organism

Intervention	percentage of participants (Number)
	End of Treatment (n=30)	Test of Cure (n=29)
Metronidazole/Ceftriaxone	96.7	100.0

Subjects with at least one causative organism identified in the pre-therapy culture or a positive pre-therapy PCR result and an appropriate post-therapy bacteriological evaluation available were analyzed. Bacteriological responses at follow-up visit was analyzed exploratively in the same way as the primary efficacy variable. (NCT00453349)
Timeframe: 28 - 42 days after completion of study drug therapy

Bacteriological Response at Follow-up Visit Microbiologically Valid

Intervention	participants (Number)
	Eradication	Eradication with recurrence, persistence
Levofloxacin Plus Metronidazole	23	11
Moxifloxacin	23	13

Bacteriological Response at Test Of Cure (TOC) Visit in Intent To Treat Population With Causative Organism

Intervention	participants (Number)
	Eradication	Eradication with recurrence, persistence
Levofloxacin Plus Metronidazole	22	4
Moxifloxacin	23	5

Bacteriological response at the TOC was analyzed exploratively in the same way as the primary efficacy variable based on the subgroup of microbiologically valid subjects. At the TOC visit, eradication was considered a bacteriological success, and persistence, presumed persistence and superinfection were considered bacteriological failures. (NCT00453349)
Timeframe: 7 - 14 days at TOC visit

Bacteriological Response at Test Of Cure (TOC) Visit Microbiologically Valid

Intervention	participants (Number)
	Eradication	Persistence, indeterminate, missing
Levofloxacin Plus Metronidazole	25	9
Moxifloxacin	28	8

The bacteriological responses was based on the results of appropriate cultures taken before and, if necessary, during treatment, at the TOC visit and within the follow-up period. Bacteriological response at the TOC visit would also be based on repeated PCR tests for N. gonorrhoeae and C. trachomatis. (NCT00453349)
Timeframe: 7 - 14 days at TOC visit

Clinical Response 7 to 14 Days After Completion of Study Drug Therapy in Per Protocol (PP) Population

Intervention	participants (Number)
	Eradication	Persistence
Levofloxacin Plus Metronidazole	22	4
Moxifloxacin	27	3

Clinical cure was defined as: Reduction of the tenderness score (modified McCormack) by > 70% and apyrexia (rectal/tympanic/oral temperature value < 38.0°C or axillary temperature value < 37.5°C) and white blood cell count < 10,500/mm^3. (NCT00453349)
Timeframe: 7 - 14 days after completion of study drug therapy

Clinical Response 7 to 14 Days After Completion of Study Drug Therapy on Intent To Treat (ITT) Population

Intervention	participants (Number)
	Clinical cure	Clinical non-success
Levofloxacin Plus Metronidazole	155	35
Moxifloxacin	152	42

"For any subject in the ITT population also valid for the PP analysis, same clinical response as in the PP analysis was applied to the ITT analysis. For those subjects in the ITT population invalid for the PP analysis, any clinical response different from clinical cure was set to non-success." (NCT00453349)
Timeframe: 7 - 14 days after completion of study drug therapy

Clinical Response at Follow-up Visit on Intent To Treat Population

Intervention	participants (Number)
	Clinical cure	Clinical non-success
Levofloxacin Plus Metronidazole	171	59
Moxifloxacin	163	62

"All successfully treated subjects and subjects evaluated asindeterminate at TOC, who were not administered an additional antibiotic therapy would have their clinical response rate assessed at the follow-up visit. Patients with missing or indeterminate outcome were treated as non-successes." (NCT00453349)
Timeframe: 28 - 42 days after completion of study drug therapy

Clinical Response at Follow-up Visit on Per Protocol Population

Intervention	participants (Number)
	Continued clinical cure	Failure, relapse, indeterminate, missing
Levofloxacin Plus Metronidazole	170	60
Moxifloxacin	166	59

Clinical response at follow up was analyzed exploratively in the same way as the primary efficacy variable. At Follow-up, the clinical response was graded as continued cure, clinical relapse, or indeterminate, of which only continued cure was considered success. Failures from end of treatment were carried forward. (NCT00453349)
Timeframe: 28 - 42 days after completion of study drug therapy

Clinical Response on Treatment for Intent To Treat Population

Intervention	participants (Number)
	Continued clinical cure	Continued failure, clinical recurrence/relapse
Levofloxacin Plus Metronidazole	158	22
Moxifloxacin	157	27

Clinical response during treatment was analyzed exploratively in the same way as the primary efficacy variable. At the During Therapy (Day 4 to 7) assessment, the clinical response was graded as clinical Improvement, clinical failure or indeterminate accordingly. Clinical improvement was considered success, all other outcomes as non-success. (NCT00453349)
Timeframe: 4 - 7 days after start of therapy

Clinical Response on Treatment for Per Protocol Population

Intervention	participants (Number)
	Clinical improvement	Failure, indeterminate, missing
Levofloxacin Plus Metronidazole	170	60
Moxifloxacin	166	59

At the During Therapy (Day 4 to 7) assessment, the clinical response was graded as clinical Improvement (severity score reduced by >30% with improvement in temperature, clinical failure (reduction in severity score of < or equal 30% and/or no improvement in temperature) or indeterminate (clinical assessment not possible to determine). (NCT00453349)
Timeframe: 4 - 7 days after start of therapy

Number of Subjects Who Received Alternative Medicine

Intervention	participants (Number)
	Clinical Improvement	Clinical failure
Levofloxacin Plus Metronidazole	181	5
Moxifloxacin	177	11

As alternative medicine any systemic antibacterial medication was considered. (NCT00453349)
Timeframe: Up to 42 days after end of treatment

Acceptability of LACTIN-V in Pre-filled Applicators

Intervention	participants (Number)
	Receiving alternative medicine	Not receiving alternative medicine
Levofloxacin Plus Metronidazole	1	189
Moxifloxacin	4	190

"Acceptability and overall satisfaction with the study product was measured using the response to the following question: I would use the product again with the following response options (strongly agree, agree, neutral, disagree, strongly disagree)~Acceptability is reported as the number of women in each group who strongly agreed or agreed with the statement that they would use the product again." (NCT00537576)
Timeframe: 35 days

Safety of LACTIN-V in Healthy Pre-menopausal Women.

Intervention	participants (Number)
Low Dose Applicator	3
Medium Dose Applicator	3
High Dose Applicator	2
Placebo Control Substance Low Dose	1
Placebo Control Substance Medium Dose	0
Placebo Control Substance High Dose	1

Safety was measured by comparing the number of women experiencing adverse events of grade 3 or higher during the study. (NCT00537576)
Timeframe: 35 days

Tolerability of LACTIN-V in a Pre-filled Applicator.

Intervention	participants (Number)
Low Dose Applicator	0
Medium Dose Applicator	0
High Dose Applicator	0
Placebo Control Substance Low Dose	0
Placebo Control Substance Medium Dose	0
Placebo Control Substance High Dose	0

Tolerability was measured as proportion of women remaining in the study, and NOT prematurely exiting the trial due to an adverse event. (NCT00537576)
Timeframe: 35 days

Article	Year
Pelvic inflammatory diseases: Updated French guidelines. Journal of gynecology obstetrics and human reproduction, 2020, Volume: 49, Issue:5 Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Ceftriaxone; Doxycycline; Female; France; Gen	2020
Antibiotic therapy for pelvic inflammatory disease: an abridged version of a Cochrane systematic review and meta-analysis of randomised controlled trials. Sexually transmitted infections, 2019, Volume: 95, Issue:1 Topics: Aminoglycosides; Anti-Bacterial Agents; Azithromycin; Cephalosporins; Clindamycin; Doxycycline; Fema	2019
Updated French guidelines for diagnosis and management of pelvic inflammatory disease. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2016, Volume: 134, Issue:2 Topics: Anti-Infective Agents; Ceftriaxone; Disease Management; Drug Therapy, Combination; Female; France; H	2016
Preventing infective complications relating to induced abortion. Best practice & research. Clinical obstetrics & gynaecology, 2010, Volume: 24, Issue:4 Topics: Abortion, Induced; Adolescent; Adult; Antibiotic Prophylaxis; Azithromycin; Cost-Benefit Analysis; D	2010
[Management of uncomplicated pelvic inflammatory disease]. Journal de gynecologie, obstetrique et biologie de la reproduction, 2012, Volume: 41, Issue:8 Topics: Anti-Bacterial Agents; Azithromycin; Ceftriaxone; Chlamydia trachomatis; Drug Resistance, Microbial;	2012
Trichomonas vaginalis vaginitis in obstetrics and gynecology practice: new concepts and controversies. Obstetrical & gynecological survey, 2013, Volume: 68, Issue:1 Topics: Anti-Infective Agents; Coinfection; Directive Counseling; Female; HIV Infections; Humans; Metronidaz	2013
Bacterial vaginosis. Transmission, role in genital tract infection and pregnancy outcome: an enigma. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2005, Volume: 113, Issue:4 Topics: Anti-Bacterial Agents; Anti-Infective Agents; Clindamycin; Disease Transmission, Infectious; Female;	2005
Infections in the female genital tract. Comprehensive therapy, 1983, Volume: 9, Issue:8 Topics: Abortion, Septic; Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Cephalosporins; En	1983
[Bacterial vaginosis]. Orvosi hetilap, 1998, Jun-07, Volume: 139, Issue:23 Topics: Anti-Bacterial Agents; Antitrichomonal Agents; Clindamycin; Female; Humans; Metronidazole; Obstetric	1998
Large bowel obstruction due to intrauterine device: associated pelvic inflammatory disease. The American surgeon, 1999, Volume: 65, Issue:12 Topics: Actinomycosis; Ampicillin; Anti-Bacterial Agents; Anti-Infective Agents; Colostomy; Diagnosis, Diffe	1999

Article	Year
Curative effect of kangfuyan capsule combined with antibiotic treatment on pelvic inflammatory disease. Pakistan journal of pharmaceutical sciences, 2021, Volume: 34, Issue:6 Spec Topics: Adolescent; Adult; Anti-Bacterial Agents; Azithromycin; Biomarkers; China; Drug Therapy, Combination	2021
A Randomized Controlled Trial of Ceftriaxone and Doxycycline, With or Without Metronidazole, for the Treatment of Acute Pelvic Inflammatory Disease. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021, 04-08, Volume: 72, Issue:7 Topics: Anti-Bacterial Agents; Ceftriaxone; Doxycycline; Female; Humans; Metronidazole; Mycoplasma genitaliu	2021
Treatment of mild-to-moderate pelvic inflammatory disease with a short-course azithromycin-based regimen versus ofloxacin plus metronidazole: results of a multicentre, randomised controlled trial. Sexually transmitted infections, 2021, Volume: 97, Issue:3 Topics: Adolescent; Adult; Anti-Bacterial Agents; Azithromycin; Drug Therapy, Combination; Female; Humans; M	2021
[Effect of Fuyanshu Capsules combined with antibiotics on inflammatory factors in patients with pelvic inflammatory disease]. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, 2019, Volume: 44, Issue:12 Topics: Anti-Bacterial Agents; Capsules; Drugs, Chinese Herbal; Female; Humans; Interleukin-10; Interleukin-	2019
Single daily dose of moxifloxacin versus ofloxacin plus metronidazole as a new treatment approach to uncomplicated pelvic inflammatory disease: a multicentre prospective randomized trial. European journal of obstetrics, gynecology, and reproductive biology, 2013, Volume: 171, Issue:1 Topics: Adolescent; Adult; Aza Compounds; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Metro	2013
Efficacy and safety of metronidazole injection for the treatment of infectious peritonitis, abdominal abscess and pelvic inflammatory diseases in Japan. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2015, Volume: 21, Issue:2 Topics: Abdominal Abscess; Adolescent; Adult; Aged; Anti-Infective Agents; Bacteria; Female; Humans; Japan;	2015
A comparative study of injection placentrex and conventional therapy in treatment of pelvic inflammatory disease. Journal of the Indian Medical Association, 2008, Volume: 106, Issue:7 Topics: Abdominal Pain; Adnexal Diseases; Adult; Alkylating Agents; Anti-Bacterial Agents; Anti-Infective Ag	2008
Levofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: a preliminary study. European journal of obstetrics, gynecology, and reproductive biology, 2009, Volume: 145, Issue:2 Topics: Adult; Anti-Bacterial Agents; Chlamydia Infections; Female; Humans; Levofloxacin; Metronidazole; Ofl	2009
A randomized double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease. International journal of STD & AIDS, 2009, Volume: 20, Issue:10 Topics: Acute Disease; Adult; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Double-Blind Method; Doxy	2009
Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG : an international journal of obstetrics and gynaecology, 2010, Volume: 117, Issue:12 Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Aza Compounds; Double-Blind Method; Drug Therapy, Co	2010
Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG : an international journal of obstetrics and gynaecology, 2010, Volume: 117, Issue:12 Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Aza Compounds; Double-Blind Method; Drug Therapy, Co	2010
Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG : an international journal of obstetrics and gynaecology, 2010, Volume: 117, Issue:12 Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Aza Compounds; Double-Blind Method; Drug Therapy, Co	2010
Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG : an international journal of obstetrics and gynaecology, 2010, Volume: 117, Issue:12 Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Aza Compounds; Double-Blind Method; Drug Therapy, Co	2010
A randomized controlled trial of coil removal prior to treatment of pelvic inflammatory disease. European journal of obstetrics, gynecology, and reproductive biology, 2003, Mar-26, Volume: 107, Issue:1 Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Device Removal; Doxycycline; Female; Hu	2003
Ciprofloxacin-tinidazole combination, fluconazole- azithromicin-secnidazole-kit and doxycycline- metronidazole combination therapy in syndromic management of pelvic inflammatory disease: a prospective randomized controlled trial. Indian journal of medical sciences, 2003, Volume: 57, Issue:12 Topics: Adolescent; Adult; Azithromycin; Ciprofloxacin; Doxycycline; Drug Therapy, Combination; Female; Fluc	2003
Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial. Sexually transmitted infections, 2006, Volume: 82, Issue:6 Topics: Administration, Oral; Adult; Anti-Infective Agents; Aza Compounds; Double-Blind Method; Drug Therapy	2006
A randomized trial of metronidazole in asymptomatic bacterial vaginosis to prevent the acquisition of sexually transmitted diseases. American journal of obstetrics and gynecology, 2007, Volume: 196, Issue:6 Topics: Administration, Intravaginal; Adult; Alabama; Anti-Infective Agents; Chlamydia Infections; Female; G	2007
[Ciprofloxacin/metronidazole vs. cefoxitin/doxycycline: comparison of two therapy schedules for treatment of acute pelvic infection]. Geburtshilfe und Frauenheilkunde, 1994, Volume: 54, Issue:6 Topics: Adult; Bacterial Infections; Bacteriological Techniques; Cefoxitin; Ciprofloxacin; Dose-Response Rel	1994
A comparison of pefloxacin/metronidazole and doxycycline/metronidazole in the treatment of laparoscopically confirmed acute pelvic inflammatory disease. European journal of obstetrics, gynecology, and reproductive biology, 1993, Volume: 50, Issue:2 Topics: Acute Disease; Chlamydia trachomatis; Double-Blind Method; Doxycycline; Drug Therapy, Combination; F	1993
Antibiotic prophylaxis to prevent post-abortal upper genital tract infection in women with bacterial vaginosis: randomised controlled trial. BJOG : an international journal of obstetrics and gynaecology, 2001, Volume: 108, Issue:4 Topics: Abortion, Induced; Administration, Intravaginal; Adolescent; Adult; Algorithms; Animals; Anti-Bacter	2001
[Treatment of acute salpingitis with tetracycline/metronidazole with or without additional balneotherapy, Augmentin or ciprofloxacin/metronidazole: a second-look laparoscopy study]. Geburtshilfe und Frauenheilkunde, 1992, Volume: 52, Issue:3 Topics: Adult; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Balneology; Clavulanic Acids; Com	1992
Incidence of pelvic inflammatory disease after first-trimester legal abortion in women with bacterial vaginosis after treatment with metronidazole: a double-blind, randomized study. American journal of obstetrics and gynecology, 1992, Volume: 166, Issue:1 Pt 1 Topics: Abortion, Induced; Chlamydia Infections; Chlamydia trachomatis; Female; Gonorrhea; Humans; Metronida	1992
Incidence of pelvic inflammatory disease after first-trimester legal abortion in women with bacterial vaginosis after treatment with metronidazole: a double-blind, randomized study. American journal of obstetrics and gynecology, 1992, Volume: 166, Issue:1 Pt 1 Topics: Abortion, Induced; Chlamydia Infections; Chlamydia trachomatis; Female; Gonorrhea; Humans; Metronida	1992
Incidence of pelvic inflammatory disease after first-trimester legal abortion in women with bacterial vaginosis after treatment with metronidazole: a double-blind, randomized study. American journal of obstetrics and gynecology, 1992, Volume: 166, Issue:1 Pt 1 Topics: Abortion, Induced; Chlamydia Infections; Chlamydia trachomatis; Female; Gonorrhea; Humans; Metronida	1992
Incidence of pelvic inflammatory disease after first-trimester legal abortion in women with bacterial vaginosis after treatment with metronidazole: a double-blind, randomized study. American journal of obstetrics and gynecology, 1992, Volume: 166, Issue:1 Pt 1 Topics: Abortion, Induced; Chlamydia Infections; Chlamydia trachomatis; Female; Gonorrhea; Humans; Metronida	1992
Intramuscular imipenem/cilastatin treatment of upper reproductive tract infection in women: efficacy and use characteristics. Chemotherapy, 1991, Volume: 37 Suppl 2 Topics: Cesarean Section; Cilastatin; Cilastatin, Imipenem Drug Combination; Consumer Behavior; Costs and Co	1991
Amoxycillin/clavulanic acid ('Augmentin') compared with a combination of aminopenicillin, aminoglycoside and metronidazole in the treatment of pelvic inflammatory disease. Pharmatherapeutica, 1989, Volume: 5, Issue:5 Topics: Adult; Aminoglycosides; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial A	1989
A comparison of ciprofloxacin with doxycycline plus metronidazole in the treatment of acute pelvic inflammatory disease. Scandinavian journal of infectious diseases. Supplementum, 1989, Volume: 60 Topics: Acute Disease; Adolescent; Adult; Bacterial Infections; Ciprofloxacin; Doxycycline; Drug Evaluation;	1989
Factors predicting abnormal hysterosalpingographic findings in patients treated for acute pelvic inflammatory disease. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 1985, Volume: 23, Issue:3 Topics: Acute Disease; Adolescent; Adult; Amoxicillin; Chlamydia Infections; Clinical Trials as Topic; Doxyc	1985
Comparison of preventive use of metronidazole and ampicillin in women with a history of pelvic inflammatory disease undergoing first-trimester abortion. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 1986, Volume: 24, Issue:5 Topics: Abortion, Induced; Adult; Ampicillin; Clinical Trials as Topic; Double-Blind Method; Female; Humans;	1986
Sulbactam/ampicillin versus metronidazole/gentamicin in the treatment of severe pelvic infections. Drugs, 1986, Volume: 31 Suppl 2 Topics: Ampicillin; beta-Lactamase Inhibitors; Cellulitis; Drug Therapy, Combination; Endometritis; Female;	1986
[Adjuvant prednisolone therapy for the prevention of adhesions after acute adnexitis]. Zentralblatt fur Gynakologie, 1988, Volume: 110, Issue:22 Topics: Ampicillin; Blood Sedimentation; Drug Therapy, Combination; Female; Humans; Metronidazole; Pelvic In	1988
Prophylactic antibiotics in women with a history of pelvic inflammatory disease undergoing first-trimester abortion. Acta obstetricia et gynecologica Scandinavica, 1987, Volume: 66, Issue:1 Topics: Abortion, Induced; Anti-Bacterial Agents; Clinical Trials as Topic; Double-Blind Method; Female; Hum	1987
[The drug combination amoxicillin-clavulanic acid compared to the triple combination ampicillin-gentamicin-metronidazole in the treatment of severe adnexal infections]. Pathologie-biologie, 1986, Volume: 34, Issue:5 Pt 2 Topics: Amoxicillin; Ampicillin; Bacterial Infections; Clavulanic Acid; Clavulanic Acids; Clinical Trials as	1986
[Prospective randomized study comparing the efficacy and tolerance of clindamycin-gentamycin versus metronidazole-gentamycin in acute utero-adnexal infections in hospitalized patients]. Revue francaise de gynecologie et d'obstetrique, 1987, Volume: 82, Issue:1 Topics: Adolescent; Clindamycin; Clinical Trials as Topic; Drug Therapy, Combination; Endometritis; Female;	1987
Metronidazole prophylaxis in elective first trimester abortion. Obstetrics and gynecology, 1985, Volume: 65, Issue:3 Topics: Abortion, Induced; Adult; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind M	1985

Article	Year
To Effectively Treat Pelvic Inflammatory Disease, Look Beyond Coverage for Gonorrhea and Chlamydia. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021, 04-08, Volume: 72, Issue:7 Topics: Ceftriaxone; Chlamydia Infections; Chlamydia trachomatis; Doxycycline; Female; Gonorrhea; Humans; Me	2021
Fitz-Hugh-Curtis Syndrome Presenting as Acute Abdomen. The American journal of medicine, 2020, Volume: 133, Issue:10 Topics: Abdomen, Acute; Anti-Bacterial Agents; Cefoxitin; Doxycycline; Exudates and Transudates; Female; Hep	2020
Sustained Simultaneous Delivery of Metronidazole and Doxycycline From Polycaprolactone Matrices Designed for Intravaginal Treatment of Pelvic Inflammatory Disease. Journal of pharmaceutical sciences, 2018, Volume: 107, Issue:3 Topics: Administration, Intravaginal; Anti-Bacterial Agents; Anti-Infective Agents; Cell Line, Tumor; Delaye	2018
Gonococcal and Chlamydial Cases of Pelvic Inflammatory Disease at 2 Canadian Sexually Transmitted Infection Clinics, 2004 to 2014: A Retrospective Cross-sectional Review. Sexually transmitted diseases, 2018, Volume: 45, Issue:4 Topics: Adolescent; Adult; Ambulatory Care Facilities; Anti-Bacterial Agents; Canada; Chlamydia Infections;	2018
Acute pelvic inflammatory disease as a rare cause of acute small bowel obstruction. Acta chirurgica Belgica, 2019, Volume: 119, Issue:5 Topics: Abdomen, Acute; Acute Disease; Adult; Anti-Bacterial Agents; Chlamydia Infections; Chlamydia trachom	2019
[Chlamydial infection with marked ascites that simulated ovarian cancer]. Ugeskrift for laeger, 2013, Apr-01, Volume: 175, Issue:14 Topics: Anti-Bacterial Agents; Ascites; Chlamydia Infections; Chlamydia trachomatis; Diagnosis, Differential	2013
Pelvic inflammatory disease in the adolescent: understanding diagnosis and treatment as a health care provider. Pediatric emergency care, 2013, Volume: 29, Issue:6 Topics: Adolescent; Anti-Bacterial Agents; Arkansas; Ceftriaxone; Centers for Disease Control and Prevention	2013
Management of Pelvic Inflammatory Disease in Selected U.S. Sexually Transmitted Disease Clinics: Sexually Transmitted Disease Surveillance Network, January 2010-December 2011. Sexually transmitted diseases, 2015, Volume: 42, Issue:8 Topics: Adolescent; Adult; Azithromycin; Centers for Disease Control and Prevention, U.S.; Chlamydia Infecti	2015
Abiotrophia/Granulicatella tubo-ovarian abscess in an adolescent virginal female. Journal of pediatric and adolescent gynecology, 2010, Volume: 23, Issue:1 Topics: Abscess; Aerococcaceae; Anti-Bacterial Agents; Carnobacteriaceae; Drug Therapy, Combination; Female;	2010
A comparison of treatment outcomes for moxifloxacin versus ofloxacin/metronidazole for first-line treatment of uncomplicated non-gonococcal pelvic inflammatory disease. International journal of STD & AIDS, 2010, Volume: 21, Issue:3 Topics: Adolescent; Adult; Anti-Infective Agents; Aza Compounds; Drug Therapy, Combination; Female; Fluoroqu	2010
Management of first-episode pelvic inflammatory disease in primary care: results from a large UK primary care database. The British journal of general practice : the journal of the Royal College of General Practitioners, 2010, Volume: 60, Issue:579 Topics: Adolescent; Adult; Anti-Infective Agents; Chlamydia Infections; Chlamydia trachomatis; Databases, Fa	2010
CDC releases 2002 guidelines for treating STDs: Part I. Diseases characterized by vaginal discharge and PID. American family physician, 2002, Nov-01, Volume: 66, Issue:9 Topics: Anti-Infective Agents; Candidiasis, Vulvovaginal; Female; Fluconazole; Humans; Metronidazole; Pelvic	2002
[EXPERIMENTAL STUDIES ON THE ASCENT OF TRICHOMONAS INFECTION IN THE FEMALE GENITALIA]. Medizinische Klinik, 1964, May-08, Volume: 59 Topics: Drug Therapy; Endometritis; Female; Genitalia, Female; Humans; Metronidazole; Pelvic Inflammatory Di	1964
Fecundity and morbidity following acute pelvic inflammatory disease treated with doxycycline and metronidazole. Archives of gynecology and obstetrics, 2003, Volume: 268, Issue:4 Topics: Abortion, Induced; Abortion, Spontaneous; Adolescent; Adult; Anti-Infective Agents; Bacteroides; Bio	2003
Pelvic abscess following microwave endometrial ablation. BJOG : an international journal of obstetrics and gynaecology, 2005, Volume: 112, Issue:1 Topics: Abscess; Adult; Anti-Infective Agents; Catheter Ablation; Ciprofloxacin; Endometrium; Female; Humans	2005
Improvement in the clinical cure rate of outpatient management of pelvic inflammatory disease following a change in therapy. Sexually transmitted infections, 2005, Volume: 81, Issue:3 Topics: Ambulatory Care; Ceftriaxone; Doxycycline; Drug Therapy, Combination; Female; Humans; Injections, In	2005
Cost-effectiveness of alternative outpatient pelvic inflammatory disease treatment strategies. Sexually transmitted diseases, 2007, Volume: 34, Issue:12 Topics: Ambulatory Care; Anti-Bacterial Agents; Cost-Benefit Analysis; Doxycycline; Drug Therapy, Combinatio	2007
Actinomyces odontolyticus isolated from the female genital tract. Journal of clinical pathology, 1984, Volume: 37, Issue:12 Topics: Actinomyces; alpha-L-Fucosidase; Cervix Uteri; Female; Humans; Intrauterine Devices; Metronidazole;	1984
Trichomonal vaginitis in Nigerian women. Tropical and geographical medicine, 1984, Volume: 36, Issue:1 Topics: Adolescent; Adult; Female; Humans; Infertility; Male; Metronidazole; Middle Aged; Nigeria; Pelvic In	1984
Metronidazole-induced psychotic disorder. The American journal of psychiatry, 1997, Volume: 154, Issue:8 Topics: Adult; Female; Humans; Metronidazole; Pelvic Inflammatory Disease; Psychoses, Substance-Induced	1997
Doppler flow characteristics in patients with pelvic inflammatory disease: responders versus nonresponders to therapy. Journal of clinical ultrasound : JCU, 1998, Volume: 26, Issue:5 Topics: Adnexa Uteri; Adult; Amoxicillin; Case-Control Studies; Clavulanic Acid; Drug Therapy, Combination;	1998
Drugs for sexually transmitted infections. The Medical letter on drugs and therapeutics, 1999, Sep-24, Volume: 41, Issue:1062 Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Antitrichomonal Agents; Azithromycin; Chlamydia	1999
Outpatient antibiotics for pelvic inflammatory disease. BMJ (Clinical research ed.), 2001, Feb-03, Volume: 322, Issue:7281 Topics: Ambulatory Care; Doxycycline; Drug Therapy, Combination; Female; Humans; Metronidazole; Pelvic Infla	2001
Amoxycillin/clavulanic acid (augmentin) compared with triple drug therapy for pelvic inflammatory disease. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 1992, Volume: 38, Issue:1 Topics: Administration, Oral; Adult; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Ampicillin;	1992
The role of laparoscopy in acute pelvic infections. European journal of obstetrics, gynecology, and reproductive biology, 1991, Jun-05, Volume: 40, Issue:1 Topics: Acute Disease; Adult; Ampicillin; Chlamydia Infections; Drug Therapy, Combination; Female; Gonorrhea	1991
Klion infusion for controlling surgical and other bacterial gynaecological febrile complications. Therapia Hungarica (English edition), 1991, Volume: 39, Issue:2 Topics: Adult; Bacterial Infections; Female; Genital Diseases, Female; Humans; Hungary; Incidence; Infusions	1991
The effect of ciprofloxacin and doxycycline plus metronidazole on lower genital tract flora in patients with proven pelvic inflammatory disease. Archives of gynecology and obstetrics, 1991, Volume: 249, Issue:2 Topics: Adult; Bacteriological Techniques; Chlamydia Infections; Chlamydia trachomatis; Ciprofloxacin; Doxyc	1991
Transvaginal-peritoneal migration of Trichomonas vaginalis as a cause of ascites. A report of two cases. The Journal of reproductive medicine, 1990, Volume: 35, Issue:2 Topics: Animals; Ascites; Female; Humans; Metronidazole; Pelvic Inflammatory Disease; Trichomonas vaginalis;	1990
Conservative approach to the management of pelvic inflammatory disease. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1990, Mar-03, Volume: 77, Issue:5 Topics: Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Female; Humans; Metronidazole; Oxytet	1990
Intravenous and oral ciprofloxacin in the treatment of proven pelvic inflammatory disease. A comparison with doxycycline and metronidazole. The American journal of medicine, 1989, Nov-30, Volume: 87, Issue:5A Topics: Administration, Oral; Bacteria; C-Reactive Protein; Ciprofloxacin; Doxycycline; Drug Therapy, Combin	1989
Standard treatment of pelvic inflammatory disease. Papua and New Guinea medical journal, 1989, Volume: 32, Issue:1 Topics: Amoxicillin; Drug Therapy, Combination; Female; Humans; Metronidazole; Papua New Guinea; Pelvic Infl	1989
Sulbactam/ampicillin in the treatment of acute pelvic inflammatory disease. Supplement to International journal of gynecology and obstetrics, 1989, Volume: 2 Topics: Adult; Ampicillin; Bacteria, Aerobic; Bacteria, Anaerobic; Cefoxitin; Doxycycline; Drug Therapy, Com	1989
Second laparoscopy after treatment of acute pelvic inflammatory disease. Obstetrics and gynecology, 1987, Volume: 69, Issue:3 Pt 1 Topics: Biopsy; Doxycycline; Drug Therapy, Combination; Endometrium; Female; Follow-Up Studies; Humans; Lapa	1987
Treating pelvic inflammatory disease with doxycycline and metronidazole or penicillin and metronidazole. Genitourinary medicine, 1986, Volume: 62, Issue:4 Topics: Adult; Chlamydia trachomatis; Doxycycline; Drug Therapy, Combination; Endometritis; Female; Humans;	1986
[Prevention of infection with metronidazole in abortion induced by PGF2 alpha]. Zentralblatt fur Gynakologie, 1986, Volume: 108, Issue:3 Topics: Abortion, Induced; Adolescent; Adult; Dinoprost; Endometritis; Female; Humans; Metronidazole; Pelvic	1986
[Bacteriologic findings and therapeutic consequences in adnexitis]. Geburtshilfe und Frauenheilkunde, 1986, Volume: 46, Issue:7 Topics: Adolescent; Adult; Aged; Bacteria; Bacterial Infections; Bacteriological Techniques; Drug Therapy, C	1986
Efficacy of different antibiotics in the treatment of pelvic inflammatory disease. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1987, Aug-15, Volume: 72, Issue:4 Topics: Ampicillin; Anti-Bacterial Agents; Doxycycline; Drug Evaluation; Drug Therapy, Combination; Female;	1987
Implications of metronidazole pharmacodynamics for therapy of trichomoniasis. Gynecologic and obstetric investigation, 1986, Volume: 21, Issue:1 Topics: Administration, Oral; Cervix Uteri; Chronic Disease; Female; Humans; Injections, Intravenous; Male;	1986
[The role of Trichomonas urogenitalis in the development of adnexitis and its treatment]. Zeitschrift fur Geburtshilfe und Gynakologie, 1969, Volume: 170, Issue:1 Topics: Adolescent; Cystitis; Female; Humans; Metronidazole; Oophoritis; Pelvic Inflammatory Disease; Salpin	1969

metronidazole and Adnexitis